TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01191892

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: gemcitabine hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vandetanib

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo of vandetanib tablet
Study: NCT00028769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bicalutamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: estramustine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: flutamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: goserelin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leuprolide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nilutamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Study: NCT01134562

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single IV injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etelcalcetide
Description: Single IV injection. The initial dose was 5 mg and dose escalation proceeded with subsequent doses of 10 mg, 20 mg, 40 mg and 60 mg.
Study: NCT04164381

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic assisted intervention
Description: Robotic treatment of the upper limb (30 sessions, 5 times a week) using a set of 4 robotic devices: Motore (Humanware); Amadeo, Diego, Pablo (Tyromotion). The training will include motor-cognitive exercises specifically selected to train spatial attention, vision and working memory, praxis, executive function, and speed of processing.
Study: NCT02538614

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idelalisib
Description: Tablets administered orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idelalisib
Description: Tablets administered orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 836826
Description: Intravenous administration as a rate-controlled infusion
Study: NCT01731301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin monotherapy will be started at a dose of 100 mg daily. After each successive week the dose of ribavirin will be increased by 100 mg increments daily as long as the hemoglobin remains greater than 10 gm/dl and/or there has not been a decline in the hemoglobin by more than 2 gms/dl from the pretreatment baseline.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon
Description: After the patient has remained on their maximal tolerated dose of ribavirin for 1 week peginterferon alpha-2b will be initiated at a dose of 1.0 mcg/kg/week. This dose was chosen because it is known to be equivalent in achieving SVR when compared to the 1.5 mcg/kg/dose and is associated with less bone marrow suppression. The dose of ribavirin will be adjusted as needed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Boceprevir
Description: Boceprevir will be added after the patient is on stable doses of ribavirin and peginterferon. The dose of ribavirin will be adjusted as needed.
Study: NCT02170324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Study: NCT04042896

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: treadmill exercise
Description: traditional aerobic exercise
Study: NCT02388919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Basic dosage, take once when limosis in the morning. If patients cannot suffer from AEs, they can get declined dosage.
Study: NCT02170324

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01259102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine transdermal patch
Description: Buprenorphine 10 mcg/hour patch applied transdermally for 7-day wear.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine transdermal patch
Description: Buprenorphine 10 mcg/hour patch applied transdermally for 7-day wear.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine transdermal patch
Description: Buprenorphine 10 mcg/hour patch applied transdermally for 7-day wear.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine transdermal patch
Description: Buprenorphine 10 mcg/hour patch applied transdermally for 7-day wear.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine transdermal patch
Description: Buprenorphine 10 mcg/hour patch applied transdermally for 7-day wear.
Study: NCT00495495

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ozone treatment
Description: Ozone treatment applied to randomly selected tooth for a period of 60 seconds at Baseline, Three, Six and Nine-Month visits.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo treatment
Description: Placebo treatment applied to randomly selected tooth for a period of 60 seconds at Baseline, Three-, Six- and Nine-Month visits.
Study: NCT02458690

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Beating the Blues (BtB)
Description: BTB is a widely used, empirically supported, stand-alone CBT program for depression designed for primary care patients and appropriate for adults with little computer experience and a 5th-6th grade reading level. BtB utilizes an interactive, multimedia format to deliver eight 50-minute, weekly therapy sessions. Although sessions are tailored to each patient's problems, general topics include challenging dysfunctional thoughts, activity scheduling, problem solving, graded exposure, task breakdown, sleep management, and relapse prevention. Patients are also assigned tailored homeworks that are customized to their needs and reviewed at the start of each session.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem Solving Treatment in Primary Care (PST-PC)
Description: PST-PC is a manualized, empirically supported CBT developed for use by healthcare professionals in primary care. The focus of the 6-10 30-minute sessions is teaching patients approaches for solving current problems contributing to depression. We are delivering PST-PC via telephone.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antidepressant Medications
Description: The IMPACT treatment manual provides guidelines for using antidepressants, such as selecting a medication, titrating, switching to another medication, managing side effects, and avoiding drug interactions. To optimize eIMPACT for CVD risk reduction, we have restricted the IMPACT list of antidepressants to SSRIs (sertraline, escitalopram, paroxetine, fluoxetine, citalopram), duloxetine, bupropion, and mirtazapine. These medications are FDA approved for the treatment of depression and are the safest from a cardiovascular perspective.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Patients randomized to usual primary care for depression are informed of their depression diagnosis, encouraged to follow-up with their Eskenazi Health primary care provider, and provided a list of local mental health services. The patient's primary care provider will receive a letter indicating that their patient has a depressive disorder and was randomized to usual care. This letter also provides a list of local mental health services. Like those in the intervention group, usual care patients continue to have access to services that are part of usual care in the targeted systems. There are no restrictions on the care received. The Eskenazi Health primary care clinics utilize a team care approach, with PCPs supported by embedded behavioral health clinicians and affiliated psychiatrists.
Study: NCT04023513

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High protein intake
Description: 6 weeks of high protein intake mainly via food (additional 1g/kg bw/d) followed by a 8 weeks resistance training (Progressive strength training in a fitness center is applied; the intensity is adjusted continuously in order to obtain a sufficient training stimulus). During the training period the protein intake remains.

Intervention type: OTHER
Group type: OTHER
Intervention: Control, no intervention
Description: No Intervention, control

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low protein intake
Description: 6 weeks of low protein intake (1g/kg bw/d) followed by a 8 weeks resistance training (Progressive strength training in a fitness center is applied; the intensity is adjusted continuously in order to obtain a sufficient training stimulus). During the training period the protein intake remains

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength training
Description: 6 weeks of different protein intake followed by a 8 weeks resistance training (Progressive strength training in a fitness center is applied; the intensity is adjusted continuously in order to obtain a sufficient training stimulus). During the training period the protein intake remains

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength training
Description: 6 weeks of different protein intake followed by a 8 weeks resistance training (Progressive strength training in a fitness center is applied; the intensity is adjusted continuously in order to obtain a sufficient training stimulus). During the training period the protein intake remains
Study: NCT01682629

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Debriefing Script
Description: A debriefing script was designed for novice instructors to facilitate a 20-minute debriefing session. It was developed in iterative steps: (a) review of PALS learning objectives; (b) categorization of script content; (c) development of scripted language; (d) formatting into a cognitive aid and (e) pilot testing script for usability with subsequent edits before implementation in the study.~All novice instructors received the scenario 2 weeks prior to the study session. Instructors randomized to scripted debriefing were also given the script with no instruction on how to use it except on the day of the study, to use and follow the script as closely as possible during the debriefing session. All instructors held a clipboard while observing the simulation session; to hold the debriefing script and/or take notes. This allowed for blinding of the video reviewers as to which study arm the team had been randomized. Debriefing sessions were limited to 20-minutes in duration.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Physical Realism Simulation
Description: High vs. Low Physical Realism Simulators A pre-programmed infant simulator was used for all simulation sessions. To create high physical realism (HiR), full simulator functions were activated (turned on) including vital sign monitoring, audio feedback, breath sounds, chest rise, heart sounds, palpable pulses, and vocalization. Low physical realism (LoR) groups had the identical simulator but the compressor was turned off, thus eliminating physical findings described above. In addition, the LoR simulator was connected to a monitor, but it only displayed the cardiac rhythm, and not pulse oximetry, respiratory rate, blood pressure, temperature and audio feedback present in the HiR group. All other aspects of the simulated resuscitation environment were standardized for all groups.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Physical Realism Simulation
Description: High vs. Low Physical Realism Simulators A pre-programmed infant simulator was used for all simulation sessions. To create high physical realism (HiR), full simulator functions were activated (turned on) including vital sign monitoring, audio feedback, breath sounds, chest rise, heart sounds, palpable pulses, and vocalization. Low physical realism (LoR) groups had the identical simulator but the compressor was turned off, thus eliminating physical findings described above. In addition, the LoR simulator was connected to a monitor, but it only displayed the cardiac rhythm, and not pulse oximetry, respiratory rate, blood pressure, temperature and audio feedback present in the HiR group. All other aspects of the simulated resuscitation environment were standardized for all groups.
Study: NCT04204811

Intervention type: OTHER
Intervention: Prehabilitation
Description: A program of personalized independent home exercises are outline for participants to complete daily. Prehabilitation coaching will continue weekly until admission for surgical tumor debulking or termination of neoadjuvant treatment for any reason.
Study: NCT02388919

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Basic dosage, take once when limosis in the morning.
Study: NCT00005044

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Casodex
Description: Orally at a dose of one 50 mg tablet per day started within (before or after) 14 days of the first LHRH agonist injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Casodex
Description: Orally at a dose of one 50 mg tablet per day started within (before or after) 14 days of the first LHRH agonist injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eulexin
Description: Orally at a dose of two 125 mg capsules three times a day for a total daily dose of 750 mg (six capsules) started within (before or after) 14 days of the first LHRH agonist injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eulexin
Description: Orally at a dose of two 125 mg capsules three times a day for a total daily dose of 750 mg (six capsules) started within (before or after) 14 days of the first LHRH agonist injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LHRH agonist
Description: LHRH agonist of choice. The manufacturer's instructions should be followed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LHRH agonist
Description: LHRH agonist of choice. The manufacturer's instructions should be followed.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: \[Prostate and any extraprostatic tumor extension + 1.0-1.5 cm margin receives 70.2 Gy (1.8 Gy/day x 39 fractions, five days/week)\] OR \[regional nodes, prostate and seminal vesicles + 1.0-1.5 cm margin will receive 46.8 Gy (1.8 Gy/day x 26 fractions, five days/week), followed by a 23.4 Gy (1.8 Gy/day x 13 fractions, five days/week) boost to the prostate and any extraprostatic tumor extension + 1.0-1.5 cm margin\]
Study: NCT01523587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: afatinib
Description: Afatinib taken once daily, continuously until disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: erlotinib
Description: erlotinib taken once daily
Study: NCT02113371

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Study: NCT00005044

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: \[Prostate and any extraprostatic tumor extension + 1.0-1.5 cm margin receives 70.2 Gy (1.8 Gy/day x 39 fractions, five days/week)\] OR \[regional nodes, prostate and seminal vesicles + 1.0-1.5 cm margin will receive 46.8 Gy (1.8 Gy/day x 26 fractions, five days/week), followed by a 23.4 Gy (1.8 Gy/day x 13 fractions, five days/week) boost to the prostate and any extraprostatic tumor extension + 1.0-1.5 cm margin\]
Study: NCT01216657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: 50 mg oral, daily, for 4 weeks, then 2 weeks without treatment, repeat at d43
Study: NCT04952831

Intervention type: OTHER
Intervention: diffusion MRI (dMRI)
Description: All participants underwent dMRI scan at baseline

Intervention type: OTHER
Intervention: diffusion MRI (dMRI)
Description: All participants underwent dMRI scan at baseline

Intervention type: OTHER
Intervention: diffusion MRI (dMRI)
Description: All participants underwent dMRI scan at baseline

Intervention type: OTHER
Intervention: diffusion MRI (dMRI)
Description: All participants underwent dMRI scan at baseline
Study: NCT01594047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketamine infusion
Description: Ketamine infusion scheme: 5mcg/Kg/min from induction od anaesthesia for 10 min, than 2,5mcg/Kg/min for 20 min and than 2 mcg/Kg/min to the end of surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketamine infusion
Description: Ketamine infusion scheme: 5mcg/Kg/min from induction od anaesthesia for 10 min, than 2,5mcg/Kg/min for 20 min and than 2 mcg/Kg/min to the end of surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone PCA
Description: Methadone administered by a PCA system (dose 2 mg, lock-out 12min.)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone PCA
Description: Methadone administered by a PCA system (dose 2 mg, lock-out 12min.)
Study: NCT00201916

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 5250 cGy/20 fractions over 28 days
Description: see above
Study: NCT01086085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adefovir
Description: Adefovir 10 mg po once daily for 36 weeks
Study: NCT00201916

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 6600 cGy/33 fractions over 45 days
Description: see above
Study: NCT01086085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [PEGASYS]
Description: Early responders: PEGASYS 180 mcg sc once weekly for 48 weeks
Study: NCT02538614

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 836826
Description: Intravenous administration as a rate-controlled infusion
Study: NCT00314977

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: doxorubicin (arm A:60 mg/m2) and arm B: 50 mg/m2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: doxorubicin (arm A:60 mg/m2) and arm B: 50 mg/m2)
Study: NCT01086085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [PEGASYS]
Description: Non-early responders: PEGASYS 180 mcg sc once weekly for 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [PEGASYS]
Description: Non-early responders: PEGASYS 180 mcg sc once weekly for 96 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [PEGASYS]
Description: Non-early responders: PEGASYS 180 mcg sc once weekly for 96 weeks
Study: NCT03757156

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Withdrawal of aspirin
Description: People who are taking aspirin stop to taking aspirin.
Study: NCT04937231

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercises
Description: For Week 1 and 2 : Treadmill 3-5days/weeks~Intensity:~50-70 vo2 peak Or HRR 60-80% Duration of 10-20 minutes For Week 3 and 4; Cycle ergometer 3-5days/weeks~Intensity:~50-70 vo2 peak Or HRR 60-80% Duration of 30-40 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance exercises
Description: For Week 1 and 2; 2 x 10 rep (unilateral leg press) 4x 12 reps (Bilateral leg press~1 x 8 rep ( unilateral arm curls For Week 3 and 4; 1 x 10 reps Shoulder press~1 x15 rep Bilateral knee extension~1 x 10 reps Bilateral arm curls

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined training
Description: For Week 1 and 2; Aerobic exercise on Treadmill along with dumbbell to perform upper limb exercises (biceps curls, side curls extensions, upright row, back fly) and used Thera band to perform lower limb exercises for 10-20 minutes For Week 3 and 4; Aerobic exercise on Treadmill along with dumbbell and Thera band to perform upper limb and lower limb exercises for 30-40 minutes
Study: NCT04721730

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PLH-YC
Description: There will be 5 weekly 2-hour sessions. The optimised PLH-YC uses a participatory, non-didactic approach to engage parents. Parents learn positive parenting skills and how to manage child behaviour problems. The program includes Session 1: One-on-One Time and Say What You See, Session 2: Praise and Rewards, Session 3: Instructions, Redirect, Rules, and Routines, Session 4: Ignore and Consequences, Session 5: Reflection and Moving On. Core activities during sessions include group discussions illustrated vignettes, role-plays, collaborative problem solving, practicing skills at home.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lecture
Description: Lecture on parenting. This is a 26-slides power-point presentation that was developed by the University of Bremen for the purpose of this study. Duration: 1 to 1.5 hours. Content: 1) Stages of child development; (2) Potential risk factors for child emotional or behaviour problems; (3) Resources and protective factors; (4) Tips: What parents can do to promote children's development.
Study: NCT03475823

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sideritis Scardica
Description: Sideritis Scardica is a popular, naturally un-caffeinated Eastern European tea extract derived from the ironwort plant
Study: NCT01352182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone hydrochloride
Description: Participants will receive a daily dose of pioglitazone at 0.5 mg/kg/dose for 5 days.
Study: NCT03475823

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sideritis Scardica
Description: Sideritis Scardica is a popular, naturally un-caffeinated Eastern European tea extract derived from the ironwort plant

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ginkgo biloba
Description: Ginkgo biloba is an extract from the ginkgo tree comprising ginkgolides and bilobalide. In this trial Ginkgo acted as an active control.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control
Description: An inert encapsulated powder provided by Finzelberg.
Study: NCT03092882

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Self-Management Program
Description: The Diabetes Self-Management Program is a platform that includes a smart meter, access to coaching 24/7, and a mobile app and website that help members manage their diabetes. The program offers diabetes education and coaching delivered entirely through the smart meter and mobile app or website.
Study: NCT00314977

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide: (arm A; 6000 mg/m2) an (arm B: 500 mg/m2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide: (arm A; 6000 mg/m2) an (arm B: 500 mg/m2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel: (arm A: 100 mg/m2) and (arm B: 75 mg/m2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel: (arm A: 100 mg/m2) and (arm B: 75 mg/m2)
Study: NCT01876498

Intervention type: PROCEDURE
Intervention: Xiaflex surgery
Description: Xiaflex surgery
Study: NCT02875548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazemetostat
Description: Tazemetostat (EPZ-6438) is a selective small molecule inhibitor of enhancer of Zeste homolog 2 (EZH2), a histone-lysine N-methyltransferase enzyme.